Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 24Lung Neoplasms 14Carcinoma, Medullary 14Neoplasm Metastasis 12Neoplasms 10Thyroid Neoplasms 8Breast Neoplasms 8Glioma 6Prostatic Neoplasms 5Glioblastoma 5Squamous Cell Carcinoma of Head and Neck 4Gliosarcoma 4Colorectal Neoplasms 4Brain Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Thyroid Cancer, Papillary 2Stomach Neoplasms 2Recurrence 2Rectal Neoplasms 2Pleural Effusion 2Kidney Neoplasms 2Familial medullary thyroid carcinoma 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Disease Progression 2

Interventions

aldesleukin 43Sunitinib 42Cyclophosphamide 30Nivolumab 29pembrolizumab 27Everolimus 27Interferon-alpha 25Bevacizumab 23Sorafenib 22Interleukin-2 20fludarabine phosphate 19Radiotherapy 18Ipilimumab 18Filgrastim 18Axitinib 18Gene Expression Profiling 16Peripheral Blood Stem Cell Transplantation 15Gemcitabine 15cabozantinib 14Radiosurgery 13fludarabine 11Doxorubicin 11Carboplatin 11Blood Specimen Collection 11temsirolimus 10atezolizumab 9Immunohistochemistry 9Etoposide 9Chemotherapy, Adjuvant 9sargramostim 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Kidney Neoplasms × vandetanib × Clear all
NCT00566995 2018-10-30

Phase II Study of Vandetanib in Individuals With Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
37 enrolled 16 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01372813 2015-10-23

Vandetanib to Treat Advanced Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
3 enrolled 10 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡